ABBV vs IBRX

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ImmunityBio exhibits a severe divergence between fundamental financial health and growth trajectory. The deterministic baseline is critical, with a Piotroski F-Score of 1/9 indicating extreme financial weakness and a negative Price/Book ratio (-14.71) signaling that liabilities exceed assets. However, this is countered by explosive YoY revenue growth of 407% and a strong current ratio of 5.10, providing a necessary liquidity runway. While analysts maintain a 'strong_buy' rating based on future potential, the current valuation is speculative and disconnected from traditional value metrics.